Can We Translate Non-inferiority Clinical Trial into Practice? Real World Outcome of Sunitinib and Pazopanib as First Line Targeted Therapy in Metastatic Renal Cell Carcinoma: UK Centre Experience

2020 ◽  
Vol 32 (5) ◽  
pp. e131
Author(s):  
S. Bandyopadhyay ◽  
P. Das ◽  
J. Davies ◽  
L. Puttarachaiah ◽  
L. Seneviratne ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Real World ◽  
Renal Cell ◽  
First Line

scholarly journals Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy

2016 ◽  
Vol 107 (7) ◽  
pp. 1013-1017 ◽  
Author(s):  
Yoshiaki Kawano ◽  
Wataru Takahashi ◽  
Masatoshi Eto ◽  
Tomomi Kamba ◽  
Hideaki Miyake ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Molecular Targeted Therapy ◽  
Interferon Α ◽  
First Line

scholarly journals STUDY OF THE EFFECTIVENESS OF TARGETED THERAPY IN METASTATIC RENAL CELL CARCINOMA PATIENTS

2017 ◽  
Vol 22 (3) ◽  
pp. 136-141
Author(s):  
Galina N. Alekseeva ◽  
L. I Gurina ◽  
M. V Volkov ◽  
E. V Evtuchenko
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Second Line ◽  
First Line ◽  
Favorable Prognosis ◽  
The One ◽  
Optimal Approach

Objective. To study the relapse-free overall survival in metastatic renal cell carcinoma (mRCC) patients after the targeted therapy and to develop optimal approach to the treatment shedule. Material and methods. The research included 88 mRCC patients of mean age of 55.5 + 9.6 years, 63 (71.6%) men and 25 (28.4%) women. 42.0% patients had a favorable prognosis, 52.3% - intermediate one and 5.7% of the cases had poor prognosis. First line targeted therapy was carried out in 88 patients, the second line - in 26 patients, and the third line - in 7 patients. Results. The one or several lines of targeted therapy allowed to achieve 20 months of a median in survival without progression of the disease. Several lines of treatment increased a median of general survival up to 42 months in comparison with the patients who were involved in the one line of treatment (a median = 30 months), p = 0.001. Side effects of targeted therapy were reversible. In the first line targeted therapy the preference was given to sunitinib, in the second line - to sorafenib. Sorafenib had an advantage in case of not light-cellular forms of renal carcinoma. In cases with favorable prognosis factors, metastases into organ parenchyma, targeted therapy with bevacizumab was carried out.

Sign in / Sign up

Export Citation Format

Share Document